BC Extra | Jul 28, 2017
Preclinical News

Novartis creates public portal for cancer knockdown data

Novartis AG (NYSE:NVS; SIX:NOVN) published its large-scale Project DRIVE cancer study online in Cell Thursday, outlining the results of nearly 8,000 gene knockdowns in roughly 400 patient derived cancer cell lines. The publication -- the...
BC Week In Review | Mar 31, 2014
Company News

Pacgen, General Biologicals Corp. deal

The companies closed a deal under which Pacgen granted General Biologicals exclusive, worldwide rights to develop and commercialize products containing PAC-113 or related peptides to treat oral, vaginal, dermatological and ophthalmic conditions. The companies announced...
BC Week In Review | Feb 3, 2014
Company News

Pacgen, General Biologicals deal

Pacgen will grant General Biologicals exclusive, worldwide rights to develop and commercialize products containing PAC-113 or related peptides to treat oral, vaginal, dermatological and ophthalmic conditions. The deal excludes transitional skin-mucous membrane areas of the...
BC Week In Review | Apr 15, 2013
Company News

Mycogen, DowElanco deal

MYCO's board approved DowElanco 's purchase of up to $75 million of restricted MYCO shares. The share price will be determined by the average daily closing prices of MYCO common stock for the 90 trading...
BC Week In Review | Feb 6, 2012
Company News

Demegen, Pacgen deal

The companies added vaginal, dermatological and ophthalmic indications to a March 2005 deal granting Pacgen worldwide rights to Demegen's PAC-113 for oral candidiasis. PAC-113 is an oral mouth rinse formulation of a 12 amino-acid antimicrobial...
BC Week In Review | Mar 28, 2005
Company News

Demegen, Pacgen deal

PRVG granted Pacgen a license to a group of peptides to treat oral diseases. PRVG previously filed an IND for the deal's lead compound for oral candidiasis. Financial terms were not disclosed. Demegen Inc. (PRVG),...
BioCentury | May 31, 2004
Product Development

Antifungal pipeline

Antifungal pipeline Company Product Status Indication Target Description Barrier Zimycan Under review in EU Candida-associated diaper dermatitits P450 sterol C-14 alpha demethylase Miconazole cream Hyphanox Ph III Vaginal cadidiasis P450 sterol C-14 alpha demethylase Oral...
BioCentury | May 31, 2004
Product Development

Cracking antifungals

For decades, the mainstays for treating fungal infections have come from two compound classes: azoles, which were introduced in the late 1960s, and polyenes, which were introduced in the 1950s. Today, there are two additional...
BC Week In Review | Jun 9, 2003
Company News

Demegen, Dow Chemical deal

The companies partnered to develop undisclosed DBOT peptides for topical diseases. Demegen Inc. (DBOT), Pittsburgh, Penn.   Dow Chemical Co. (DOW), Midland, Mich.   Business: Drug delivery  ...
BC Week In Review | Nov 11, 2002
Clinical News

P113D inhaled antimicrobial agent regulatory update

The FDA granted Orphan Drug Designation for P113D to treat infections in cystic fibrosis (CF) patients. The compound is in preclinical development. Demegen Inc. (DBOT), Pittsburgh, Penn.   Product: P113D inhaled antimicrobial agent   Business:...
Items per page:
1 - 10 of 70
BC Extra | Jul 28, 2017
Preclinical News

Novartis creates public portal for cancer knockdown data

Novartis AG (NYSE:NVS; SIX:NOVN) published its large-scale Project DRIVE cancer study online in Cell Thursday, outlining the results of nearly 8,000 gene knockdowns in roughly 400 patient derived cancer cell lines. The publication -- the...
BC Week In Review | Mar 31, 2014
Company News

Pacgen, General Biologicals Corp. deal

The companies closed a deal under which Pacgen granted General Biologicals exclusive, worldwide rights to develop and commercialize products containing PAC-113 or related peptides to treat oral, vaginal, dermatological and ophthalmic conditions. The companies announced...
BC Week In Review | Feb 3, 2014
Company News

Pacgen, General Biologicals deal

Pacgen will grant General Biologicals exclusive, worldwide rights to develop and commercialize products containing PAC-113 or related peptides to treat oral, vaginal, dermatological and ophthalmic conditions. The deal excludes transitional skin-mucous membrane areas of the...
BC Week In Review | Apr 15, 2013
Company News

Mycogen, DowElanco deal

MYCO's board approved DowElanco 's purchase of up to $75 million of restricted MYCO shares. The share price will be determined by the average daily closing prices of MYCO common stock for the 90 trading...
BC Week In Review | Feb 6, 2012
Company News

Demegen, Pacgen deal

The companies added vaginal, dermatological and ophthalmic indications to a March 2005 deal granting Pacgen worldwide rights to Demegen's PAC-113 for oral candidiasis. PAC-113 is an oral mouth rinse formulation of a 12 amino-acid antimicrobial...
BC Week In Review | Mar 28, 2005
Company News

Demegen, Pacgen deal

PRVG granted Pacgen a license to a group of peptides to treat oral diseases. PRVG previously filed an IND for the deal's lead compound for oral candidiasis. Financial terms were not disclosed. Demegen Inc. (PRVG),...
BioCentury | May 31, 2004
Product Development

Antifungal pipeline

Antifungal pipeline Company Product Status Indication Target Description Barrier Zimycan Under review in EU Candida-associated diaper dermatitits P450 sterol C-14 alpha demethylase Miconazole cream Hyphanox Ph III Vaginal cadidiasis P450 sterol C-14 alpha demethylase Oral...
BioCentury | May 31, 2004
Product Development

Cracking antifungals

For decades, the mainstays for treating fungal infections have come from two compound classes: azoles, which were introduced in the late 1960s, and polyenes, which were introduced in the 1950s. Today, there are two additional...
BC Week In Review | Jun 9, 2003
Company News

Demegen, Dow Chemical deal

The companies partnered to develop undisclosed DBOT peptides for topical diseases. Demegen Inc. (DBOT), Pittsburgh, Penn.   Dow Chemical Co. (DOW), Midland, Mich.   Business: Drug delivery  ...
BC Week In Review | Nov 11, 2002
Clinical News

P113D inhaled antimicrobial agent regulatory update

The FDA granted Orphan Drug Designation for P113D to treat infections in cystic fibrosis (CF) patients. The compound is in preclinical development. Demegen Inc. (DBOT), Pittsburgh, Penn.   Product: P113D inhaled antimicrobial agent   Business:...
Items per page:
1 - 10 of 70